Physician profile

David M Chang

Internal Medicine · San Diego, CA

NPI 1073596342

$7,803.04

in general payments reported to CMS, 2019-2025

44 companies · $726 in 2025

The $726 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,492.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,733.71 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $1,063.18 2019-2024 Spiriva Respimat, Ofev, Stiolto Respimat
Astrazeneca Pharmaceuticals LP $728.31 2019-2025 Tezspire, Fasenra
Regeneron Healthcare Solutions, INC. $659.38 2019-2024 Dupixent
Pfizer INC. $401.03 2019-2025
Genzyme Corporation $355.82 2021-2025
Mylan Specialty L.P. $313.73 2019-2024 Yupelri
Actelion Pharmaceuticals US, INC. $307.48 2019-2023 Opsumit, Uptravi
Grifols USA, LLC $239.79 2023-2025 Prolastin-C Liquid
Amgen INC. $203.05 2020-2025 Evenity, Prolia, Prolia
Takeda Pharmaceuticals U.S.A., INC. $167.41 2021-2022
Insmed, INC. $160.97 2020-2025 Arikayce, Brinsupri
Paratek Pharmaceuticals, INC. $152.87 2020-2021
Merck Sharp & Dohme LLC $147.04 2019-2024 Dificid, Zerbaxa, Recarbrio
Advanced Respiratory, INC $125.67 2020-2021
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $113.91 2022-2025 Ozempic, Wegovy, Rybelsus
Electromed, INC. $89.34 2019-2023 Smartvest
Melinta Therapeutics, LLC $83.83 2022-2023 Orbactiv, Kimyrsa, Vabomere
Philips North America LLC $55.70 2022-2023
Janssen Pharmaceuticals, INC $50.58 2021
Sanofi Pasteur INC. $48.53 2021-2025
Seqirus USA INC $47.75 2024-2025 Fluad, Flucelvax
Hospira, INC. $44.03 2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $39.11 2021-2024 Trulance, Xifaxan
Shionogi INC $37.98 2021-2022
Phadia US INC. $37.87 2024 Immunocap
Circassia INC. $37.00 2019
Teva Pharmaceuticals USA, INC. $36.27 2020-2021
Alnylam Pharmaceuticals INC. $32.27 2022
Verona Pharma, INC. $26.74 2025 Ohtuvayre
Daiichi Sankyo INC. $26.06 2022
Aimmune Therapeutics, INC. $25.46 2025 Vowst
Octapharma USA, INC. $23.98 2024 Octagam Immune Globulin (Human)
Novartis Pharmaceuticals Corporation $20.97 2024
Gilead Sciences, INC. $20.16 2021
Pulmonx Corporation $19.05 2020
Vyera Pharmaceuticals, LLC $18.74 2020
Inogen, INC. $18.59 2019
Pentax of America, INC. $18.39 2021
Jazz Pharmaceuticals INC. $16.25 2019
Resmed Corp $14.46 2019
Medline Industries LP $14.17 2021
Bayer Healthcare Pharmaceuticals INC. $13.27 2019
Allergan, INC. $13.14 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David M Chang

$7,803.04

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $726 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/3121/david-m-chang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.